Download PDF        
May 23, 2013


Algeta and Lumiphore Announce Further Expansion of their Global Partnership for the Development of Targeted Alpha-Pharmaceutical Cancer Therapeutics and Companion Diagnostics.

Richmond, CA, U.S.A., May 2, 2013. Lumiphore Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4 bifunctional chelator technology and has extended the collaboration to include additional chelator families. These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs). Full press release available for download.